AZATHIOPRINE


Trade Names	AZASAN AZATHIOPRINE IMURAN
Synonyms	Azamune Azapress Azasan Azathioprine Azathioprinum BW-57-322 Berkaprine Immunoprin 50 Imuran Kentaprine NSC-39084 Oprisine 50
Status
Molecule Category	Free-form
ATC	L04AX01
UNII	MRK240IY2L
EPA CompTox	DTXSID4020119


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LMEKQMALGUDUQG-UHFFFAOYSA-N
Smiles	Cn1cnc([N+](=O)[O-])c1Sc1ncnc2[nH]cnc12
InChI	InChI=1S/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C9H7N7O2S
Molecular Weight	277.27
AlogP	1.15
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	115.42
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	19.0

Metabolites Network

visNetwork

Pharmacology

Mechanism of Action	Action	Reference
Amidophosphoribosyltransferase inhibitor	INHIBITOR	PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	107
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters	-	-	-	-	4

Cross References

Resources	Reference
ChEBI	2948
ChEMBL	CHEMBL1542
DrugBank	DB00993
DrugCentral	269
FDA SRS	MRK240IY2L
Human Metabolome Database	HMDB0015128
Guide to Pharmacology	7120
KEGG	C06837
PharmGKB	PA448515
PubChem	2265
SureChEMBL	SCHEMBL4278
ZINC	ZINC000004258316

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).